Literature DB >> 12176902

Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1.

Irene M Pedersen1, Shinichi Kitada, Lorenzo M Leoni, Juan M Zapata, James G Karras, Nobuhiro Tsukada, Thomas J Kipps, Yong Sung Choi, Frank Bennett, John C Reed.   

Abstract

Chronic lymphocytic leukemia (CLL) B cells have defects in apoptosis pathways and therefore accumulate in vivo. However, when removed from the patient and cultured in vitro, these malignant cells rapidly undergo apoptosis. Recent studies suggest that leukemia cell survival is influenced by interactions with nonleukemia cells in the microenvironment of lymph nodes, marrow, and other tissues. To model such cell-cell interactions in vitro, we cultured freshly isolated CLL B cells with a follicular dendritic cell line, HK. CLL B cells cocultured with HK cells were protected from apoptosis, either spontaneous or induced by treatment with anticancer drugs. Protection against spontaneous apoptosis could also be induced by coculturing the CLL B cells with normal dendritic cells (DCs) or with a CD40-ligand (CD154)-expressing fibroblast cell line. Examination of the expression of several apoptosis-regulatory proteins revealed that coculture with HK cells or DCs induced up-regulation of the antiapoptotic Bcl-2 family protein Mcl-1 in CLL B cells, whereas CD40 ligation increased expression of Bcl-X(L). Cell-cell contact was required for HK-induced protection, and introducing neutralizing antibodies against various adhesion molecules showed that CD44 was involved in HK-mediated survival, whereas CD40, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were not. Anti-CD44 antibodies also blocked Mcl-1 induction by HK cells. Mcl-1 antisense oligonucleotides reduced leukemia cell expression of Mcl-1, and significantly suppressed HK-induced protection against apoptosis, whereas control oligonucleotides had no effect. Thus, HK cells protect CLL B cells against apoptosis, at least in part through a CD44-dependent mechanism involving up-regulation of Mcl-1, and this mechanism is distinct from that achieved by CD40 ligation. Consequently, the particular antiapoptotic proteins important for CLL survival may vary depending on the microenvironment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176902

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  74 in total

1.  Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.

Authors:  Januario E Castro; Johanna Melo-Cardenas; Mauricio Urquiza; Juan S Barajas-Gamboa; Ramin S Pakbaz; Thomas J Kipps
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.

Authors:  Davorka Messmer; Jessie-F Fecteau; Morgan O'Hayre; Ila S Bharati; Tracy M Handel; Thomas J Kipps
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

4.  Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.

Authors:  Montserrat Cols; Carolina M Barra; Bing He; Irene Puga; Weifeng Xu; April Chiu; Wayne Tam; Daniel M Knowles; Stacey R Dillon; John P Leonard; Richard R Furman; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

Review 5.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

6.  Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Yelena V Krupnik; Kenneth Dunner; David J McConkey; Michael J Keating; Peng Huang
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

7.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Authors:  P B Knudsen; B Hanna; S Ohl; L Sellner; T Zenz; H Döhner; S Stilgenbauer; T O Larsen; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528

Review 8.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

9.  Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.

Authors:  Amit K Mittal; Nagendra K Chaturvedi; Karan J Rai; Christine E Gilling-Cutucache; Tara M Nordgren; Margaret Moragues; Runqing Lu; Rene Opavsky; Greg R Bociek; Dennis D Weisenburger; Javeed Iqbal; Shantaram S Joshi
Journal:  Mol Med       Date:  2014-07-15       Impact factor: 6.354

10.  Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

Authors:  Suping Zhang; Christina C N Wu; Jessie-F Fecteau; Bing Cui; Liguang Chen; Ling Zhang; Rongrong Wu; Laura Rassenti; Fitzgerald Lao; Stefan Weigand; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.